Apellis Pharmaceuticals, Inc.
General ticker "APLS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.8B (TTM average)
Apellis Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 43.8%.
Estimated limits based on current volatility of 0.0%: low 41.02$, high 41.06$
Factors to consider:
- Total employees count: 705 (-0.1%) as of 2024
- Top business risk factors: Insufficient funding, Product commercialization failure, Regulatory and compliance, Geopolitical risks, Litigation risks
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [18.76$, 38.50$]
- 2026-12-31 to 2027-12-31 estimated range: [18.19$, 37.65$]
Financial Metrics affecting the APLS estimates:
- Positive: with PPE of 192.5 at the end of fiscal year the price was neutral
- Positive: -4.95 < Operating profit margin, % of 5.52
- Negative: Operating cash flow per share per price, % of 1.44 <= 6.65
- Negative: negative Industry operating cash flow (median)
- Positive: Investing cash flow per share per price, % of -0.01 > -0.63
- Negative: Inventory ratio change, % of 2.89 > 0.80
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: 19.44 < Shareholder equity ratio, % of 34.42 <= 42.58
Short-term APLS quotes
Long-term APLS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $396.59MM | $781.37MM | $1,003.78MM |
| Operating Expenses | $913.71MM | $946.35MM | $948.36MM |
| Operating Income | $-517.12MM | $-164.98MM | $55.43MM |
| Non-Operating Income | $-9.38MM | $-31.74MM | $-31.32MM |
| Interest Expense | $29.58MM | $40.39MM | $44.33MM |
| R&D Expense | $354.39MM | $327.57MM | $295.85MM |
| Income(Loss) | $-526.50MM | $-196.72MM | $24.11MM |
| Taxes | $2.13MM | $1.16MM | $1.72MM |
| Profit(Loss)* | $-528.63MM | $-197.88MM | $22.39MM |
| Stockholders Equity | $194.52MM | $228.54MM | $370.15MM |
| Inventory | $146.36MM | $82.48MM | $142.56MM |
| Assets | $788.73MM | $885.05MM | $1,075.26MM |
| Operating Cash Flow | $-594.74MM | $-87.87MM | $45.33MM |
| Capital expenditure | $0.77MM | $0.40MM | $0.31MM |
| Investing Cash Flow | $-0.67MM | $-0.40MM | $-0.31MM |
| Financing Cash Flow | $394.50MM | $149.24MM | $8.88MM |
| Earnings Per Share** | $-4.45 | $-1.60 | $0.18 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.